Interleukin species selection

Scientifically-soimd safety evaluation of interleukins and interferons should include studies that demonstrate the extent of species specificity of the molecule selection of a pharmacologically active species single- and multiple-dose toxicology and pharmacokinetic profiles an assessment of reversibility of toxic effects the timeframe and consequences of antibody production in animals the influence of route of administration, formulation, and dosing schedule on pharmacokinetics, and on local and systemic toxicity. 

---